← All trials
NCT04990921
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 2, 2021
- Primary completion
- Jul 1, 2031
- Completion date
- Jul 1, 2031
- First posted
- Aug 5, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LouisvilleLead sponsor
- University of LouisvilleReponsible party - principal investigator
- University of LouisvilleOverall official - principal investigator
- James Graham Brown Cancer CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.